Evaluation of cost-effectiveness of peginterferon plus ribavirin for chronic hepatitis C treatment and direct-acting antiviral agents among HIV-infected patients in the prison and community settings
ConclusionsChronic HCV/HIV co-infected patients with genotype 1 and 6 in the community setting could benefit from DAAs in Taiwan.
Source: Journal of Microbiology, Immunology and Infection - Category: Microbiology Source Type: research
More News: Allergy & Immunology | Databases & Libraries | Health Insurance | Hepatitis | Hepatitis C | Insurance | Microbiology | Study | Taiwan Health | Virology